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Abstract
Objective
Current guidelines call for HIV-infected women to deliver via scheduled Caesarean when
the maternal HIV viral load (VL) is >1,000 copies/ml. We describe the mode of delivery
among HIV-infected women and evaluate adherence to relevant recommendations.
Study Design
We performed a population-based surveillance analysis of HIV-infected pregnant women in
Philadelphia from 2005 to 2013, comparing mode of delivery (vaginal, scheduled Caesar-
ean, or emergent Caesarean) by VL during pregnancy, closest to the time of delivery
(1,000 copies/ml versus an unknown VL or VL >1,000 copies/ml) and associated factors
in multivariable analysis.
Results
Our cohort included 824 deliveries from 648 HIV-infected women, of whom 69.4% had a VL
1,000 copies/ml and 30.6% lacked a VL or had a VL >1,000 copies/ml during pregnancy,
closest to the time of delivery. Mode of delivery varied by VL: 56.6% of births were vaginal,
30.1% scheduled Caesarean, and 13.3% emergent Caesarean when the VL was1,000
copies/ml; when the VL was unknown or >1,000 copies/ml, 32.9% of births were vaginal,
49.9% scheduled Caesarean and 17.5% emergent Caesarean. In multivariable analyses,
Hispanic women (adjusted odds ratio (AOR) 0.17, 95% Confidence Interval (CI) 0.04–0.76)
and non-Hispanic black women (AOR 0.27, 95% CI 0.10–0.77) were less to likely to deliver
via scheduled Caesarean compared to non-Hispanic white women. Women who delivered
prior to 38 weeks’ gestation (AOR 0.37, 95% CI 0.18–0.76) were also less likely to deliver
via scheduled Caesarean compared to women who delivered after 38 weeks’ gestation. An
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interaction term for race and gestational age at delivery was significant in multivariable anal-
ysis. Non-Hispanic black (AOR 0.06, 95% CI 0.01–0.36) and Hispanic women (AOR 0.03,
95% CI 0.00–0.59) were more likely to deliver prematurely and less likely to deliver via
scheduled C-section compared to non-Hispanic white women. Having a previous Caesar-
ean (AOR 27.77, 95% CI 8.94–86.18) increased the odds of scheduled Caesarean delivery.
Conclusions
Only half of deliveries for women with an unknown VL or VL >1,000 copies/ml occurred via
scheduled Caesarean. Delivery prior to 38 weeks, particularly among minority women,
resulted in a missed opportunity to receive a scheduled Caesarean. However, even when
delivering at or after 38 weeks’ gestation, a significant proportion of women did not get a
scheduled Caesarean when indicated, suggesting a need for focused public health inter-
ventions to increase the proportion of women achieving viral suppression during pregnancy
and delivering via scheduled Caesarean when indicated.
Introduction
The success of preventative interventions has decreased mother-to-child transmission (MTCT)
of HIV in industrialized countries to less than 2% [1]. The key to this dramatic decrease is the
availability and prescription of antiretroviral therapy (ART) to HIV-infected pregnant women
for the purpose of achieving viral suppression before delivery. However, too many women do
not achieve viral suppression by delivery [2]. Prior studies indicate that women with a HIV
viral load (VL)>1,000 copies/ml at the time of delivery are at greater risk of MTCT of HIV
compared to women with a VL1,000 copies/ml. [3]. In these women, delivery via scheduled
Caesarean section (C-section) is an effective intervention proven to reduce the risk of HIV
transmission. The protective effect of a scheduled C-section before the onset of labor and rup-
ture of membranes was first described in the 1990s by clinical trials comparing scheduled C-
section versus usual care in international cohorts [4–5]. Studies conducted in the modern ART
era show that delivery via scheduled C-section, rather than vaginal delivery or emergent C-sec-
tion, most effectively reduces the risk of vertical transmission when maternal VL is elevated
near delivery [1].
These findings led the American College of Obstetricians and Gynecologists (ACOG) Com-
mittee on Obstetric Practice and the United States Department of Health and Human Services
(DHHS) Panel to issue recommendations regarding scheduled C-sections. These guidelines
call for HIV-infected women with an VL>1,000 copies/ml to be counseled on the potential
benefit of a scheduled C-section to prevent MTCT; receive ART during pregnancy; have a C-
section scheduled at 38 weeks' gestation; and receive intravenous zidovudine during labor
[6,7]. However, little is known regarding compliance with these guidelines. Potential factors
that result in women not delivering via scheduled C-section include lack of engagement in pre-
natal care, late HIV diagnosis, birth before the scheduled C-section, and patient/provider
choice [7–10]. The primary objective of this study was to evaluate adherence to current guide-
lines recommending a scheduled C-section for HIV-infected women with an unknown VL or
VL>1,000 copies/ml for HIV-infected women delivering in Philadelphia from 2005–2013.
Additionally, maternal demographic and clinical factors associated with delivery via scheduled
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C-section for HIV-infected women with an unknown VL or VL>1,000 copies/ml were evalu-
ated through analysis of HIV surveillance data.
Materials and Methods
Study Population
We identified all HIV-infected women who delivered a live infant between 2005 and 2013
where the mother was a resident of Philadelphia or the birth occurred in Philadelphia. Multiple
gestation deliveries were included as a single observation. Demographic, clinical, and engage-
ment in care information for each mother-infant pair were abstracted from the Philadelphia
Enhanced Perinatal Surveillance (EPS) project. EPS is a population-based surveillance system
of HIV-infected pregnant women that includes 15 participating areas reporting a high inci-
dence of HIV. The Philadelphia EPS is conducted through the Philadelphia Department of
Public Health as a part of the Centers for Disease Control and Prevention's (CDC) surveillance
cooperative agreement. The overarching goals of the EPS are to assist in timely evaluation of
perinatal prevention efforts, monitor the implementation of the US Public Health Service rec-
ommendations for counseling and voluntary testing of pregnant women, and to assess ART
use among HIV-infected pregnant women to prevent MTCT [11]. EPS identifies HIV-exposed
infants through active case finding, utilizing reports from healthcare providers, delivery hospi-
tals, laboratory reporting, and matching HIV-infected women with vital records. EPS data are
obtained from medical chart abstractions (HIV care, prenatal care, intrapartum care, pediatric
care records, and vital statistic records) by a trained abstractor. In our study, laboratory values,
such as VL during pregnancy, closest to the time of delivery, were determined by merging EPS
with the enhanced HIV/AIDS Reporting System (eHARS). eHARS is a surveillance system of
all reported HIV/AIDS cases in Pennsylvania; the combined dataset for the state and Philadel-
phia is maintained by the Pennsylvania and Philadelphia Department of Public Health. The
Philadelphia Department of Public Health Institutional Review Board exempted this study
from review.
Variables
Outcome Variables. Our primary outcome, mode of delivery, was dichotomously catego-
rized as scheduled C-section versus other modes of delivery (emergent C-section or vaginal
delivery). Our definition for a scheduled C-section was based upon that of the DHHS which
categorizes a C-section as scheduled if the procedure is done before the onset of labor or rup-
ture of membranes. Emergent C-section was defined as a Caesarean performed after the onset
of labor or rupture of membranes. When the mode of delivery was unknown, the case was
removed from the analysis (n = 12).
Clinical Variables of Interest. Demographic variables included age, race/ethnicity, mari-
tal status, health insurance type, HIV risk exposure category, and illicit drug use. Age at deliv-
ery was categorized as 16–24, 25–34 and35; race was categorized as non-Hispanic white,
non-Hispanic black, and Hispanic; marital status as married and unmarried; and health insur-
ance as public (Medicaid, Medicare, state funded insurance, and other publicly funded insur-
ance), private (private insurance, HMO private insurance, and self-insured), and uninsured.
HIV risk exposure was determined using the Centers for Disease Control and Prevention’s
hierarchy of reported exposure categories [12]. The HIV risk exposure variable dichotomized
risk as either including intravenous drug use or all other HIV risk exposures including hetero-
sexual and perinatal transmission. Illicit drug use was considered active if drug use occurred
during pregnancy and included the use of amphetamines, barbiturates, benzodiazepines,
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cocaine, crack cocaine, heroin, hallucinogens, methadone, marijuana, methamphetamines, opi-
ates, or other illegal drugs.
Mode of delivery was evaluated by the dichotomous maternal VL variable. The VL variable
reflected the VL during pregnancy, closest to the time of delivery and was classified as VL
1,000 copies/ml vs. unknown VL or a VL>1,000 copies/ml. Women lacking a recorded VL
at delivery are considered to be at greater risk for MTCT compared to women with a VL
1,000 and were therefore included with women with a VL>1,000 copies/ml. Other clinical
variables of interest included history of a previous C-section delivery, quality of prenatal care
as measured by the Kessner Index, ART receipt (at any point during pregnancy), and timing of
ART initiation. The Kessner Index, a validated measure of adequacy of prenatal care which
takes into account the month in which prenatal care began, gestational weeks at time of deliv-
ery and number of prenatal care visits, classifies care as adequate, intermediate or inadequate
[13]. Classification as adequate indicates that the initial prenatal visit occurred within the first
trimester (at or before 13 weeks) and a minimum of 9 prenatal care visits was attended if deliv-
ery occurred after 35 weeks’ gestation. Classification as inadequate/no prenatal care indicates
that the initial prenatal care visit occurred in the third trimester (after 27 weeks) or fewer than
5 visits were after 18 weeks’ gestation. All other combinations of prenatal care initiation, num-
ber of prenatal care visits, and gestational age of delivery are considered intermediate. ART
receipt during pregnancy was determined by provider documentation during the prenatal visits
and hospitalizations; additional information on type or appropriateness of antiretroviral used
was available but often incomplete. Timing of ART initiation during pregnancy was classified
as ART initiation by the first or second trimester as opposed to ART initiated within the third
trimester. Deliveries were also categorized by hospital site. Timing of HIV diagnosis was cate-
gorized as prior to pregnancy, during pregnancy, and at or soon after delivery based on when
the HIV diagnosis was made.
Infant level variables included birth type, gestational age and HIV status. Birth type was cat-
egorized as single or multiple gestations. Since CDC and ACOG guidelines stipulate that a
scheduled C-section for the purpose of minimizing vertical HIV transmission should be at 38
weeks’ gestation, the gestational age variable was classified as<38 weeks’ gestation or38
weeks’ gestation [6–7]. Infant HIV status was determined using the CDC case definition for
HIV-exposed infants under 18 months of age. HIV positivity required a positive result on two
separate specimens (not including cord blood) from one or more HIV virologic tests (HIV
nucleic acid detection, HIV antigen test, or HIV isolation)[14].
Statistical Analysis
We examined maternal demographic, behavioral and clinical/engagement in care characteris-
tics based on the mode of delivery and stratified by maternal viral load during pregnancy, clos-
est to the time of delivery from 2005 to 2013. The relationship between infant characteristics
such as birth type (single/multiple), infant HIV status and gestational age at birth and mode of
delivery was also analyzed using univariable analysis. A multivariable logistic regression model
was used to determine the odds of receiving a scheduled C-section when the VL was unknown
or>1,000 copies/ml adjusting for demographic, clinical and engagement in care variables,
delivery hospital site variable (data not shown), and clustering at the level of the mother due to
repeated births during the study period. We hypothesized that non-Hispanic black women
were more likely to deliver preterm prior to 38 weeks’ gestation and an additional multivariable
analysis was conducted to adjust for an interaction between gestational age and race/ethnicity.
Secondary analysis included a sensitivity analysis excluding women without a VL during preg-
nancy. In addition, we evaluated the proportion of women receiving scheduled C-sections after
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38 weeks’ gestation with a third trimester VL>1,000 copies/mL and associations between
scheduled C-section and timing of HIV diagnosis, timing of ART initiation, and mode of deliv-
ery. Statistical analyses were conducted using STATA 12 (StataCorp, College Station, TX).
Results
Study Population
Our cohort included 824 deliveries from 648 HIV-infected women of whom 51.3% were
between 25–34 years of age, 79.0% were non-Hispanic black, and 84.8% had an HIV risk factor
other than injection drug use. Of the total study population, 39.1% received adequate, 38.3%
intermediate, and 22.6% inadequate prenatal care (Table 1). The majority of women (74.8%)
were diagnosed prior to pregnancy, 172 (20.9%) during pregnancy, and 36 (4.4%) at time of
delivery or soon after delivery. ART was prescribed during the majority of pregnancies (85.3%)
and typically initiated by the first or second trimester (64.7%).
Mode of delivery overall and by maternal HIV viral load
Of the total study population of 824 deliveries, 407 pregnancies (49.4%) resulted in vaginal
deliveries, 297 (36.0%) in scheduled C-sections and 120 (14.6%) in emergent C-sections. In
univariable analysis stratified by maternal VL, for women with a VL1,000 copies/ml, mode
of delivery differed by maternal age, HIV risk factor, previous C-section, and birth type; for
women with a VL>1,000 copies/ml, mode of delivery differed by previous C-section, quality
of prenatal care, ART prescription during pregnancy, time of HIV diagnosis, and gestational
age at delivery. (Table 1).
Close to thirty percent of the cohort (n = 252, 30.6%) had an unknown VL or a VL>1,000
copies/ml during pregnancy, closest to the time of delivery while 69.4% (n = 572) had a VL
1,000 copies/ml. Out of 252 deliveries with VL>1,000 copies/ml or unknown VL, 49.9% had
a scheduled C-section, 32.9% a vaginal delivery, and 17.5% an emergent C-section (Table 1). In
comparison, out of 572 deliveries with an VL1,000 copies/ml, 30.1% had a scheduled C-sec-
tion, 56.6% had a vaginal delivery, and 13.3% had an emergent C-section. Overall, 31.6% of the
cohort delivered before 38 weeks’ gestation. Women without a VL or VL>1,000 copies/ml and
delivering before 38 weeks’ gestation were less likely to deliver via scheduled C-section (34.7%
vs. 59.6%, p-value<0.001) and more likely to deliver via emergent C-section (30.7% vs. 8.6%,
p-value<0.001) compared to women delivering at or after 38 weeks’ gestation. ART was initi-
ated by the first or second trimester for 73.6% (n = 421/572) of women with a VL1,000 cop-
ies/mL compared to 44.4% (n = 112/252) of women with a VL>1,000 copies/mL or without a
VL during pregnancy (p-value<0.001).
Of 824 HIV-exposed infants, 16 (1.9%) were confirmed HIV-infected. Seventy-five percent
(n = 12) of the HIV-infected infants were born to women without a VL or a VL>1,000 copies/
ml during pregnancy, closest to the time of delivery. Of the 12 HIV-infected infants born to
women without a VL or a VL>1,000 copies/ml at delivery, 8 were born via vaginal delivery, 2
via emergent C-section, and 2 via a scheduled C-section.
Maternal Characteristics by Gestational Age at Delivery
A substantial portion of our cohort (n = 260, 31.6%) delivered before 38 weeks’ gestation
(Table 2). Within univariable analysis, women who used drugs were more likely to deliver<38
weeks’ gestation compared to women who did not use drugs (41.8% vs. 22.9%), less likely to
have received adequate prenatal care (25.2% vs. 39.1%), less likely to have an ART prescription
during pregnancy (29.4% vs. 85.3%), and less likely to have initiated ART by the first or second
Mode of Delivery among HIV-InfectedWomen
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Table 1. Mode of Delivery among HIV-InfectedWomenwith a Viral Load1,000 and Unknown VL or VL >1,000 copies/ml by Demographic, Behav-
ioral and Clinical Characteristics, 2005–2013—Enhanced Perinatal Surveillance, Philadelphia.a
Viral Load 1000 copies/ml (n = 572) Viral Load >1000 copies/ml or unknown (n = 252)
Total
Population
(n = 824)
Scheduled C-
section
Emergent C-
section
Vaginal
Delivery
p-
value
Scheduled C-
section
Emergent C-
section
Vaginal
Delivery
p-
value
Total, n (%) 172 (30.1) 76 (13.3) 324 (56.6) 125 (49.9) 44 (17.5) 83 (32.9)
Age 0.006 0.257
16–24 211 (25.6) 37 (25.0) 19 (12.8) 92 (62.2) 38 (60.3) 10 (15.9) 15 (23.8)
25–34 423 (51.3) 82 (27.3) 39 (13.0) 179 (59.7) 59 (48.0) 23 (18.7) 41 (33.3)
 35 190 (23.1) 53 (42.7) 18 (14.5) 53 (42.7) 28 (42.4) 11 (16.7) 27 (40.9)
Race 0.153 0.055
White, Non-
Hispanic
105 (12.7) 27 (40.9) 9 (13.6) 30 (45.5) 27 (69.2) 2 (5.1) 10 (25.6)
Black, Non-Hispanic 651 (79.0) 129 (27.9) 60 (13.0) 273 (59.1) 89 (47.1) 36 (19.1) 64 (33.9)
Hispanic 68 (8.3) 16 (36.4) 7 (15.9) 21 (47.7) 9 (37.5) 6 (25.0) 9 (37.5)
Marital Status 0.826 0.643
Unmarried 670 (81.3) 134 (29.7) 59 (13.1) 259 (57.3) 107 (49.1) 40 (18.4) 71 (32.6)
Married 154 (18.7) 38 (31.7) 17 (14.2) 65 (54.2) 18 (52.9) 4 (11.8) 12 (35.3)
Insurance
Coverage
0.729 0.733
Public 642 (77.9) 134 (31.0) 54 (12.5) 244 (56.5) 107 (51.0) 34 (16.2) 69 (32.9)
Private 94 (11.4) 21 (28.4) 10 (13.5) 43 (58.1) 9 (45.0) 4 (20.0) 7 (35.0)
Uninsured 88 (10.7) 17 (25.8) 12 (18.2) 37 (56.1) 9 (40.9) 6 (27.3) 7 (31.8)
HIV Risk Factor 0.004 0.968
Other Riskb 699 (84.8) 137 (27.6) 68 (13.7) 292 (58.8) 101 (50.0) 35 (17.3) 66 (32.7)
Injection Drug Use 125 (15.2) 35 (46.7) 8 (10.7) 32 (42.7) 24 (48.0) 9 (18.0) 17 (34.0)
Drug Use During
Pregnancy
0.256 0.116
No 635 (77.1) 137 (29.4) 58 (12.5) 271 (58.2) 91 (53.9) 29 (17.2) 49 (29.0)
Yes 189 (22.9) 35 (33.0) 18 (17.0) 53 (50.0) 34 (41.0) 15 (18.1) 34 (41.0)
Previous Cesarean
Delivery
<0.001 <0.001
No 673 (81.7) 77 (16.2) 73 (15.4) 324 (68.4) 76 (38.2) 40 (20.1) 83 (41.7)
Yes 151 (18.3) 95 (96.9) 3 (3.1) 0 (0.0) 49 (92.5) 4 (7.6) 0 (0.0)
Quality of Prenatal
Care
0.899 0.004
Adequate 322 (39.1) 73 (28.5) 37 (14.5) 146 (57) 41 (62.1) 6 (9.1) 19 (28.8)
Intermediate 316 (38.3) 74 (32) 28 (12.1) 129 (55.8) 44 (51.8) 21 (24.7) 20 (23.5)
Inadequate 186 (22.6) 25 (29.4) 11 (12.9) 49 (57.7) 40 (39.6) 17 (16.8) 44 (43.6)
ART Prescription
During Pregnancy
0.649 <0.001
No 121 (14.7) 5 (21.7) 3 (13.0) 15 (65.2) 33 (33.7) 14 (14.3) 51 (52.0)
Yes 703 (85.3) 167 (30.4) 73 (13.3) 309 (56.3) 92 (59.7) 30 (19.5) 32 (20.8)
ART Initiation by
1st/2nd Trimester
0.764 <0.001
No 291 (35.3) 42 (27.8) 20 (13.3) 89 (58.9) 56 (40.0) 25 (17.9) 59 (42.1)
Yes 533 (64.7) 130 (30.9) 56 (13.3) 235 (55.8) 69 (61.6) 19 (17.0) 24 (21.4)
Time of HIV
Diagnosis
0.337 0.004
Prior to Pregnancy 616 (74.8) 140 (31.1) 56 (12.4) 254 (56.4) 90 (54.2) 25 (15.1) 51 (30.7)
(Continued)
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trimester (27.2% vs. 64.7%). While not statistically significant in univariable analysis, a larger
proportion of non-Hispanic black (31.5%) and Hispanic (38.2%) women delivered before 38
weeks’ gestation compared to non-Hispanic white women (27.6%).
Maternal factors associated with a scheduled C-section among women
with a VL>1,000 copies/ml
In univariable analyses, we found that non-Hispanic black women (Unadjusted Odds Ratio
(UOR) 0.38, 95% CI 0.17–0.83) and Hispanic women (UOR 0.25, 95% CI 0.09–0.76) were less
likely to receive a scheduled C-section compared to non-Hispanic white women (Table 3).
Women over the age of 35 years old (UOR 0.48, 95% CI 0.24–0.97) were also less likely to
receive a scheduled C-section compared to younger women. Women with a previous C-section
(UOR 19.80, 95% CI 6.85–56.98) and those prescribed ART during pregnancy (UOR 2.97, 95%
CL 1.73–5.10) were more likely to deliver via C-section than their counterparts. Women who
delivered prior to 38 weeks’ gestation were less likely to deliver by scheduled C-section (UOR
0.36, 95% CI 0.21–0.61) compared to those with term deliveries. Women who were diagnosed
with HIV at or soon after delivery (UOR 0.17, 95% CI 0.06–0.46) and women who received
inadequate prenatal care (UOR 0.40, 95% CI 0.21–0.75) were also less likely to deliver by
scheduled C-section compared to women who were diagnosed prior to pregnancy and women
who received adequate prenatal care. Women prescribed ART during pregnancy (UOR 2.97,
95% CI 1.44–5.10) and initiating ART by the first or second trimester (UOR 2.43, 95% CI
1.44–4.09) were more likely to deliver via scheduled C-section compared to women who had
not initiated ART by the first or second trimester or women not prescribed ART during preg-
nancy in unadjusted analysis.
Table 1. (Continued)
Viral Load 1000 copies/ml (n = 572) Viral Load >1000 copies/ml or unknown (n = 252)
Total
Population
(n = 824)
Scheduled C-
section
Emergent C-
section
Vaginal
Delivery
p-
value
Scheduled C-
section
Emergent C-
section
Vaginal
Delivery
p-
value
During Pregnancy 172 (20.9) 29 (25.0) 19 (16.4) 68 (58.6) 30 (53.6) 11 (19.6) 15 (26.8)
At/After Delivery 36 (4.4) 3 (50.0) 1 (16.7) 2 (3.33) 5 (16.7) 8 (26.7) 17 (56.7)
Gestational Age at
Delivery
0.088 <0.001
< 38 weeks 260 (31.6) 47 (29.6) 29 (18.2) 83 (52.2) 35 (34.7) 31 (30.7) 35 (34.7)
 38 weeks 564 (68.5) 125 (30.3) 47 (11.4) 241 (58.4) 90 (59.6) 13 (8.6) 48 (31.8)
Birth Type 0.013 0.157
Single 803 (97.5) 165 (29.7) 71 (12.8) 320 (57.6) 122 (49.4) 42 (17.0) 83 (33.6)
Multiple 21 (2.5) 7 (43.8) 5 (31.3) 4 (25.0) 3 (60.0) 2 (40.0) 0 (0.0)
Infant's HIV Status 0.626 0.07
HIV Positive 16 (1.9) 2 (50.0) 1 (25.0) 1 (25.0) 2 (16.7) 2 (16.7) 8 (66.7)
HIV Negative 658 (79.9) 139 (30.1) 60 (13.0) 263 (56.9) 104 (53.1) 33 (16.8) 59 (30.1)
Indeterminate 150 (18.2) 31 (29.3) 15 (14.2) 60 (56.6) 19 (43.2) 9 (20.5) 16 (36.4)
Abbreviation: ART, Antiretroviral Therapy
a Infants of a multiple gestation were counted as one case. Analyses were restricted to women without an unknown/missing documentation of mode of
delivery. Delivery hospital information was not included for conﬁdentiality purposes.
b Other Risk included heterosexual and perinatal transmissions.
P-values are derived from Chi-square and Fisher’s Exact Test. Boldface font, p < 0.05
doi:10.1371/journal.pone.0144592.t001
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In multivariable analyses, race, gestational age at delivery, and history of a previous C-sec-
tion remained significant. Women who delivered prior to 38 weeks’ gestation (0.37, 95% CI
0.18–0.76), Hispanic (AOR 0.17, 95% CI 0.04–0.76), and non-Hispanic black women (AOR
0.27, 95% CI 0.10–0.77) were less likely to deliver via scheduled C-section compared to women
Table 2. Maternal characteristics among HIV-infected pregnant women by gestational age, Philadelphia, 2005–2013.
<38 Weeks' Gestation at Time of Delivery
(n = 260)
38 Weeks' Gestation at Time of Delivery
(n = 564)
p-
value
Age at Delivery (yr) 0.082
16–24 55 (26.1) 156 (73.9)
25–34 136 (32.2) 287 (67.8)
35 69 (36.3) 121 (63.7)
Race/Ethnicity 0.34
White, Non-Hispanic 29 (27.6) 76 (72.4)
Black, Non-Hispanic 205 (31.5) 446 (68.5)
Hispanic 26 (38.2) 42 (61.8)
Marital Status 0.787
Unmarried 210 (31.3) 460 (68.7)
Married 50 (32.5) 104 (67.5)
Insurance Coverage 0.08
Public 215 (33.5) 427 (66.5)
Private 23 (24.5) 71 (75.5)
Uninsured 22 (25.0) 66 (75.0)
HIV Risk Factor 0.114
Other Riska 213 (30.5) 486 (69.5)
Injection Drug Use 47 (37.6) 78 (62.4)
Drug Use During Pregnancy 0.001
No 181 (28.5) 454 (71.5)
Yes 79 (41.8) 110 (58.2)
Previous Cesarean Delivery 0.062
No 222 (33.0) 451 (67.0)
Yes 38 (25.2) 113 (74.8)
Quality of Prenatal Care 0.001
Adequate 81 (25.2) 241 (74.8)
Intermediate 103 (32.6) 213 (67.4)
Inadequate 76 (40.9) 110 (59.1)
ART Prescription During
Pregnancy
0.002
No 53 (43.8) 68 (56.2)
Yes 207 (29.4) 496 (70.6)
ART Initiated By 1st/2nd
Trimester
<0.001
No 115 (39.5) 176 (60.5)
Yes 145 (27.2) 388 (72.8)
Time of HIV Diagnosis
Prior to Pregnancy 189 (30.7) 427 (69.3) 0.116
During Pregnancy 54 (31.4) 118 (68.6)
At/After Time of Delivery 17 (47.2) 19 (52.8)
a Other Risk included heterosexual and perinatal transmissions.
doi:10.1371/journal.pone.0144592.t002
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Table 3. Factors Associated with Delivery via Scheduled C-Section among HIV-InfectedWomenwith an Unknown Viral Load or Viral Load >1,000
copies/ml (n = 321), Philadelphia, 2005–2013.
UOR (95% CI) p-
value
AOR (95% CI) p-
value
AOR (95% CI) with
Interaction
p-
value
Age at Delivery (yr)
16–24 1 [Reference] 1 [Reference] 1 [Reference]
25–34 0.61 (0.33–1.10) 0.099 0.62 (0.28–1.38) 0.256 0.56 (0.24–1.31) 0.178
35 0.48 (0.24–0.97) 0.042 0.42 (0.17–1.02) 0.056 0.39 (0.15–1) 0.050
Race/Ethnicity
White, Non-Hispanic 1 [Reference] 1 [Reference] 1 [Reference]
Black, Non-Hispanic 0.38 (0.17–0.83) 0.016 0.27 (0.10–0.77) 0.014 0.14 (0.05–0.41) <0.001
Hispanic 0.25 (0.09–0.76) 0.014 0.17 (0.04–0.76) 0.021 0.08 (0.01–0.47) 0.005
Marital Status
Unmarried 1 [Reference] 1 [Reference] 1 [Reference]
Married 1.16 (0.55–2.43) 0.690 0.39 (0.15–1.07) 0.068 0.36 (0.13–1.01) 0.051
Insurance Coverage
Public 1 [Reference] 1 [Reference] 1 [Reference]
Private 0.79 (0.31–2.07) 0.639 0.83 (0.20–3.42) 0.792 0.89 (0.21–3.72) 0.868
Uninsured 0.67 (0.29–1.56) 0.355 0.54 (0.11–2.49) 0.431 0.48 (0.09–2.61) 0.394
HIV Risk Factor
Other Risk 1 [Reference] 1 [Reference] 1 [Reference]
Injection Drug Use 0.93 (0.50–1.74) 0.819 1.17 (0.49–2.83) 0.720 1.13 (0.45–2.83) 0.792
Drug Use During Pregnancy
No 1 [Reference] 1 [Reference] 1 [Reference]
Yes 0.60 (0.34–1.03) 0.065 0.68 (0.28–1.64) 0.388 0.78 (0.3–1.98) 0.594
Previous Caesarean Delivery
No 1 [Reference] 1 [Reference] 1 [Reference]
Yes 19.8 (6.85–
56.98)
<0.001 27.77 (8.94–
86.18)
<0.001 31.38 (9.44–104.29) <0.001
Quality of Prenatal Care
Adequate 1 [Reference] 1 [Reference] 1 [Reference]
Intermediate 0.65 (0.34–1.25) 0.199 0.60 (0.27–1.35) 0.221 0.62 (0.26–1.44) 0.267
Inadequate 0.40 (0.21–0.75) 0.004 0.46 (0.15–1.38) 0.165 0.46 (0.14–1.49) 0.195
ART Prescription during Pregnancy
No 1 [Reference] 1 [Reference] 1 [Reference]
Yes 2.97 (1.73–5.10) <0.001 1.25 (0.40–3.85) 0.696 1.24 (0.38–4.1) 0.722
ART initiated by 1st/2nd trimester
No 1 [Reference] 1[Reference] 1 [Reference]
Yes 2.43 (1.44–4.09) <0.001 1.12 (0.41–3.11) 0.821 1.43 (0.50–4.12) 0.507
Gestational Age at Time of Delivery
<38 weeks 0.36 (0.21–0.61) <0.001 0.37 (0.18–0.76) 0.007 0.42 (0.13–1.37) 0.149
38 weeks 1 [Reference] 1 [Reference] 1 [Reference]
Time of HIV Diagnosis
Prior to Pregnancy 1 [Reference] 1 [Reference] 1 [Reference]
During Pregnancy 0.97 (0.54–1.76) 0.931 1.70 (0.78–3.73) 0.188 1.89 (0.79–4.48) 0.151
At/After Delivery 0.17 (0.06–0.46) <0.001 0.32 (0.06–1.67) 0.177 0.35 (0.06–2.09) 0.248
Race/Ethnicity x Gestational Age at Time of
Delivery
Black and <38 weeks - - - 0.06 (0.01–0.36) 0.002
Hispanic and < 38 weeks - - - 0.03 (0.00–0.59) 0.021
Delivery hospital information was not included for conﬁdentiality purposes.
AOR, adjusted odds ratio; CI, conﬁdence interval; UOR, unadjusted odds ratio; bold face font, p <0.05.
doi:10.1371/journal.pone.0144592.t003
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delivering at or after 38 weeks’ gestation and non-Hispanic white women. Women with a pre-
vious C-section (AOR 27.77, 95% CI 8.94–86.18) were also more likely to have a C-section
delivery than women with no prior C-sections. Women delivered in eight hospitals, mostly
university affiliated, located in Philadelphia and surrounding areas. There was no statistically
significant difference in the prevalence of scheduled C-sections and VL distribution at delivery
by delivery hospital (data not shown).
Addition of a race/ethnicity and gestational age interaction term resulted in effect modifica-
tion within the multivariable logistic regression model. Independently, age became newly sig-
nificant and race remained significantly associated with receipt of a scheduled C-section. In
addition, the interaction term was statistically significant; suggesting the association between
race and a scheduled C-section varies by gestational age at the time of delivery. Non-Hispanic
black women (AOR 0.06, 95% CI 0.01–0.36) and Hispanic women (AOR 0.03, 95% CI 0.00–
0.59) who delivered<38 weeks’ gestation were less likely to have a scheduled C-section when
VL was unknown or>1,000 copies/ml during pregnancy, closest to the time of delivery. Of the
women with an unknown VL or VL>1,000 copies/ml who delivered prior to 38 weeks’ gesta-
tion, 75.0% (n = 9/12) of white women delivered via scheduled C-section compared to 30.8%
(n = 24/78) of non-Hispanic black and 18.2% (n = 2/11) Hispanic women (data not shown).
History of a previous C-section remained significant. A sensitivity analysis excluding unknown
VL (n = 84) showed no statistically significant difference in study findings.
HIV-infected women with VL >1,000 copies/ml in third trimester
Viral load information during the third trimester was available for the majority of our study
population. For women with a VL>1,000 copies/ml in the third trimester (n = 130), 49
(37.7%) delivered before 38 weeks’ gestation. For the remaining 81 women, 74.1% had a sched-
uled C-section, 8.6% an emergent C-section, and 17.3% a vaginal delivery. Of women deliver-
ing after 38 weeks’ gestation with a third trimester VL>1,000, 55.6% had initiated ART by the
second trimester and 72.8% had been diagnosed with HIV prior to pregnancy.
Discussion
In this cohort of HIV-infected pregnant women in Philadelphia, guidelines recommending a
scheduled C-section for women with a VL>1,000 copies/ml were not consistently met. Our
findings identified multiple missed opportunities for HIV-infected pregnant women including
a high rate of premature delivery (<38 weeks’ gestation) particularly among women of color,
lack of viral load information and viral suppression during pregnancy, and the failure to sched-
ule C-sections for women with a VL> 1,000 copies/ml.
While the majority of women delivered after 38 weeks’ gestation, Hispanic and non-His-
panic black women were significantly more likely to deliver prior to 38 weeks’ gestation com-
pared to non-Hispanic white women. Premature delivery contributed to significant racial
disparities: non-Hispanic black and Hispanic women were over 70% less likely to receive a
scheduled C-section when indicated compared to non-Hispanic white women even after con-
trolling for demographic, clinical, and engagement in care variables. Nationally, the percentage
of early term (37 0/7-38 6/7 weeks' gestation) deliveries via scheduled C-section without medi-
cal indication has increased 86% from 1995 to 2009, mostly among white, insured, and college
educated women [9]. Within our study, women of color were more likely to deliver prior to 38
weeks’ gestation and less likely to deliver via scheduled C-section compared to non-Hispanic
white women. According to national data, the proportion of preterm deliveries is higher
among black women compared to white women (16.53% vs. 10.29%, respectively) [15].
Women delivering prematurely often present with ruptured membranes, increasing the
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likelihood of MTCT [1]. This clinical finding calls for improved surveillance and interventions
to reduce the risk of prematurity, particularly among women of color. Univariable analyses
showed that women with inadequate prenatal care, prenatal drug use, and no or late ART use
during pregnancy were also more likely to deliver prematurely (Table 2). An association
between prenatal substance use and preterm delivery has been previously reported [16]. Offer-
ing concurrent substance abuse treatment with prenatal care has been shown to decrease the
likelihood of preterm delivery and may be applicable to HIV-infected women with prenatal
substance use [16]. Measures to reduce the risk of premature labor, including early and contin-
ued prenatal care, should be emphasized, particularly among women with elevated VLs at pre-
sentation for care. Preventative interventions such as weekly progesterone injections or the use
of tocolytic agents have been applied with varying degrees of success in the general population
[17, 18]; however, tools to identify pregnant women for whom these and other interventions
will effectively reduce preterm birth are lacking. Of note, C-section deliveries scheduled before
38 weeks’ gestation may increase associated costs and infant complications [19]. Within our
study, non-Hispanic white women delivering prior to 38 weeks’ gestation were more likely to
deliver via scheduled C-section compared to non-Hispanic black and Hispanic women. How-
ever, the reduced risk of vertical transmission associated with scheduled C-sections before 38
weeks’ may not offset the risk of maternal and infant morbidity as MTCT in our cohort was
less than the national average (2%) even with moderate compliance to current recommenda-
tions. Early prenatal care and timely initiation of ART during pregnancy are better candidates
for improving maternal and fetal outcomes.
A large proportion of our cohort had an unknown VL or a VL>1,000 copies/ml near deliv-
ery, calling for increased attention to guidelines for virologic testing as well as for achieving
viral suppression during pregnancy. The majority of our cohort (85.3%) received ART during
pregnancy; slightly more than the national EPS average (84%) and other reported frequencies
in U.S. and international studies [11, 20]. However, virologic control was still quite low: only
69.4% of women had a VL1,000 copies/ml during pregnancy, closest to the time of delivery,
suggesting that complete viral suppression was even lower. According to a 2011 estimate from
the CDC, 77% of HIV-infected adults prescribed ART achieve viral suppression (HIV VL
200 copies/ml) [21]. Of note, our study involved women at various levels of the HIV care con-
tinuum, including women newly diagnosed with HIV. Typically a pregnant woman has multi-
ple interactions with the healthcare system within a short period of time. Prenatal care visits
offer opportunities to discuss the initiation of and adherence to ART. Qualitative analyses have
shown that HIV-infected pregnant women have a high level of motivation to be adherent to
ART in order to prevent MTCT of HIV compared to non-pregnant women; these findings sup-
port the fact that viral suppression by delivery is an achievable goal if psychosocial and struc-
tural barriers to ART adherence are addressed early in a woman’s pregnancy [22]. Viral
suppression at delivery is very likely when ART is initiated before 20 weeks’ gestation and is
possible with appropriate treatment even much later in pregnancy [23]. However, socioeco-
nomic challenges, stigma, isolation, mental health and substance abuse [24, 25] can interfere
with ART adherence in this critical period of women’s lives and these factors may have contrib-
uted to our findings. Tools are needed to identify barriers to ART adherence along with inter-
ventions to link and retain pregnant HIV-infected women in care. Interventions for the general
HIV population such as case management [26] and patient navigator [27] involvement have
successfully increased linkage, retention, and viral suppression and could improve clinical out-
comes for HIV-infected women during pregnancy and postpartum.
Even among women delivering at or after 38 weeks’ gestation, 25% with a VL>1,000 copies/
ml did not receive a scheduled C-section. This finding calls for efforts to increase the proportion
of women delivering via Caesarean when indicated. The substantial effectiveness of a scheduled
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C-section delivery in reducing MTCT of HIV in the pre-combination (cART) era and post-
cART era is well established [2, 4]. While we were unable to detect a difference in surgical prac-
tices based on delivery hospital, patient preferences and/or provider perceptions or bias may
have contributed to the low prevalence of scheduled C-sections. Studies have shown that physi-
cian factors such as gender, financial incentives, convenience, and education/training influences
the percentage of women receiving C-sections nationally [28–32]. However, financial reim-
bursement is an unlikely driver of our findings as type of insurance coverage was not associated
with receipt of a scheduled C-section among HIV-infected women with a VL>1,000 copies/mL
in either univariable or multivariable analysis.
Our study has several limitations. Relying on surveillance data obtained mainly from chart
abstractions revealed errors associated with missing values, misclassification, and under-
reporting of data. Some women lacked a VL during pregnancy; however, a sensitivity analysis
was performed to ensure that unknown VL at delivery during pregnancy closest to the time of
delivery did not impact major study findings. Secondly, patients or providers were not con-
tacted to understand factors associated with mode of delivery. Future qualitative analyses are
needed to further evaluate these factors. EPS abstraction forms did not collect data on whether
a C-section was scheduled and not performed but discerning this information would be helpful
for future studies. The data are also limited to a single geographic region and may not be appli-
cable to the general population of HIV-infected pregnant women. Finally, the use of the Kess-
ner index limited the interpretation of the adequacy of prenatal care to only one index. Results
may have been altered slightly if other tools for measuring adequacy were used. Despite limita-
tions, the EPS system provided ongoing surveillance and data abstracts from various sources
over a long period of time.
In conclusion, only half of deliveries for women with an unknown VL or VL>1,000 copies/
ml occurred via scheduled C-section. Delivery prior to 38 weeks, particularly among minority
women, resulted in a missed opportunity to receive a scheduled C-section. However, even
when delivering at or after 38 weeks’ gestation, a quarter of the women with a VL>1,000 cop-
ies/ml had a vaginal delivery or emergent C-section, suggesting a need for focused public health
interventions to increase the proportion of women achieving viral suppression during preg-
nancy and delivering via scheduled C-section when indicated.
Acknowledgments
The authors would like to thank the Philadelphia Department of Public Health AIDS Activities
Coordinating Office for providing the data sources. Disclaimer: The views expressed in this
paper are those of the authors. No official endorsement by the Philadelphia Department of
Public Health, Centers for Diseases Control and Prevention, or National Institutes of Health is
intended or should be inferred.
Author Contributions
Conceived and designed the experiments: DRT FMM JWA BRY EAA GA KAB. Performed the
experiments: DRT FMM. Analyzed the data: DRT FMM JWA EAA. Contributed reagents/
materials/analysis tools: KAB. Wrote the paper: DRT FMM JWA BRY EAA GA KAB.
References
1. Suy A, Hernandez S, Thorne C, Lonca M, Lopez M, Coll O. Current guidelines on management of HIV-
infected pregnant women: Impact on mode of delivery. Eur J Obstet Gynecol Reprod Biol. 2008; 139
(2):127–132. doi: 10.1016/j.ejogrb.2007.12.007 PMID: 18262324
Mode of Delivery among HIV-InfectedWomen
PLOSONE | DOI:10.1371/journal.pone.0144592 December 14, 2015 12 / 14
2. Momplaisir FM, Brady KA, Fekete T, Thompson DR, Diez Roux A, Yehia BR. Time of HIV diagnosis
and engagement in prenatal care impact virologic outcomes of pregnant women with HIV. PLoS ONE.
2015; 10(7): e0132262. doi: 10.1371/ journal.pone.0132262 PMID: 26132142
3. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human
immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999; 341
(6):394–402. PMID: 10432324
4. Parazzini F, Ricci E, Di Cintio E, Chiaffarino F, Chatenoud L, Pardi G, et al. Elective caesarean-section
versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet.
1999; 353(9158):1035–1039. PMID: 10199349
5. Read J, Scherpbier H, Boer K. The mode of delivery and the risk of vertical transmission of human
immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies: the International Peri-
natal HIV Group. N Engl J Med. 1999; 340:977–987. PMID: 10099139
6. Practice CoO. ACOG committee opinion scheduled Cesarean delivery and the prevention of vertical
transmission of HIV infection. Number 234, May 2000 (replaces number 219, August 1999). Int J
Gynaecol Obstet. 2001; 73(3):279. PMID: 11424912
7. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Rec-
ommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-InfectedWomen for Maternal Health
and Interventions to Reduce Perinatal HIV Transmission in the United States. 2015. Available: https://
aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf.
8. Short CE, Douglas M, Smith J, Taylor G. Preterm delivery risk in women initiating antiretroviral therapy
to prevent HIV mother-to-child transmission. HIV Med. 2014; 15(4):233–238. doi: 10.1111/hiv.12083
PMID: 24025074
9. Kozhimannil KB, Macheras M, Lorch SA. Trends in Childbirth before 39 Weeks’Gestation without Med-
ical Indication. Med Care. 2014; 52(7):649–657. doi: 10.1097/MLR.0000000000000153 PMID:
24926713
10. Béhague DP, Victora CG, Barros FC. Consumer demand for caesarean sections in Brazil: informed
decision making, patient choice, or social inequality? A population based birth cohort study linking eth-
nographic and epidemiological methods. BMJ. 2002; 324(7343):942. PMID: 11964338
11. Centers for Disease Control and Prevention. Enhanced perinatal surveillance—15 areas, 2005–2008.
HIV Surveillance Supplemental Report 2011. In. http://www.cdc.gov/hiv/topics/surveillance/resources/
reports/.
12. Centers for Disease Control and Prevention. HIV Surveillance Report, 2013. 2015; 25. Available: http://
www.cdc.gov/hiv/library/reports/surveillance/.
13. Kotelchuck M. An evaluation of the Kessner adequacy of prenatal care index and a proposed adequacy
of prenatal care utilization index. Am J Public Health. 1994; 84(9):1414–1420. PMID: 8092364
14. Centers for Disease Control and Prevention. Revised surveillance case definitions for HIV infection
among adults, adolescents, and children aged <18 Months and for HIV infection and AIDS among chil-
dren aged 18 months to <13 years. MMWR 2008; 57(No. RR-10).
15. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Matthews T. Births: final data for 2011. National
Vital Statistics Report. 2013; 62(1).
16. Goler NC, Armstrong MA, Taillac CJ Osejo VM. Substance abuse treatment linked with prenatal visits
improves perinatal outcomes: A new standard. Journal of Perinatology. 2008; 28 (9): 597–603. doi: 10.
1038/jp.2008.70 PMID: 18580882
17. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent
preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348(24):2379–
2385. PMID: 12802023
18. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007; 357(5):477–487. PMID:
17671256
19. Villar J, Carroli G, Zavaleta N, Donner A, Wojdyla D, Faundes A, et al. Maternal and neonatal individual
risks and benefits associated with caesarean delivery: multicentre prospective study. BMJ. 2007; 335
(7628):1025. PMID: 17977819
20. Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent
mother-to-child-transmission: systematic review and meta-analysis. AIDS (London, England). 2012;
26(18):2361–2373.
21. Centers_for_Disease_Control_Prevention. Vital signs: HIV prevention through care and treatment—
United States. MMWR. Morbidity and mortality weekly report. 2011; 60(47):1618.
22. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretro-
viral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a
Mode of Delivery among HIV-InfectedWomen
PLOSONE | DOI:10.1371/journal.pone.0144592 December 14, 2015 13 / 14
systematic review and meta-analysis. AIDS. 2012; 26(16):2039–2052. doi: 10.1097/QAD.
0b013e328359590f PMID: 22951634
23. Aebi-Popp K, Mulcahy F, Glass TR, Rudin C, Martinez de Tejada B, Bertisch B, et al. Missed opportuni-
ties among HIV-positive women to control viral replication during pregnancy and to have a vaginal deliv-
ery. J Acquir Immune Defic Syndr. 2013; 64(1):58–65. doi: 10.1097/QAI.0b013e3182a334e3 PMID:
23842074
24. Turan JM, Nyblade L. HIV-related stigma as a barrier to achievement of global PMTCT and maternal
health goals: a review of the evidence. AIDS Behav. 2013; 17(7):2528–2539. doi: 10.1007/s10461-
013-0446-8 PMID: 23474643
25. Myer L, Zulliger R, Bekker L-G, Abrams E. Systemic delays in the initiation of antiretroviral therapy dur-
ing pregnancy do not improve outcomes of HIV-positive mothers: a cohort study. BMC Pregnancy
Childbirth. 2012; 12(1):94.
26. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, et al. Efficacy of a
brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS.
2005; 19(4):423–431. PMID: 15750396
27. Bradford JB, Coleman S, CunninghamW. HIV System Navigation: an emerging model to improve HIV
care access. AIDS Patient Care STDS. 2007; 21(S1): S-49–S-58.
28. Mitler LK, Rizzo JA, Horwitz SM. Physician gender and cesarean sections. J Clin Epidemiol. 2000; 53
(10):1030–1035. PMID: 11027936
29. Dale Tussing A, Wojtowycz MA. The effect of physician characteristics on clinical behavior: cesarean
section in New York State. Soc Sci Med. 1993; 37(10):1251–1260. PMID: 8272903
30. Burns LR, Geller SE, Wholey DR. The effect of physician factors on the cesarean section decision.
Med Care. 1995; 33(4):365–382. PMID: 7731278
31. Stafford RS. The impact of nonclinical factors on repeat cesarean section. JAMA. 1991; 265(1):59–63.
PMID: 1984126
32. Keeler EB, Brodie M. Economic incentives in the choice between vaginal delivery and cesarean sec-
tion. The Milbank Quarterly. 1993:365–404. PMID: 8413067
Mode of Delivery among HIV-InfectedWomen
PLOSONE | DOI:10.1371/journal.pone.0144592 December 14, 2015 14 / 14
